MX2014002693A - Uso de 1h-quinazolina-2,4-dionas para usarse en la prevencion o el tratamiento de epilepsia fotosensible. - Google Patents
Uso de 1h-quinazolina-2,4-dionas para usarse en la prevencion o el tratamiento de epilepsia fotosensible.Info
- Publication number
- MX2014002693A MX2014002693A MX2014002693A MX2014002693A MX2014002693A MX 2014002693 A MX2014002693 A MX 2014002693A MX 2014002693 A MX2014002693 A MX 2014002693A MX 2014002693 A MX2014002693 A MX 2014002693A MX 2014002693 A MX2014002693 A MX 2014002693A
- Authority
- MX
- Mexico
- Prior art keywords
- prevention
- diones
- quinazoline
- photosensitive epilepsy
- treatment
- Prior art date
Links
- 201000003040 photosensitive epilepsy Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 201000005070 reflex epilepsy Diseases 0.000 title abstract 2
- SDQJTWBNWQABLE-UHFFFAOYSA-N 1h-quinazoline-2,4-dione Chemical class C1=CC=C2C(=O)NC(=O)NC2=C1 SDQJTWBNWQABLE-UHFFFAOYSA-N 0.000 title 1
- 229940098747 AMPA receptor antagonist Drugs 0.000 abstract 1
- 239000000775 AMPA receptor antagonist Substances 0.000 abstract 1
- 230000002860 competitive effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2011/050687 WO2013036224A1 (en) | 2011-09-07 | 2011-09-07 | Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014002693A true MX2014002693A (es) | 2014-06-04 |
Family
ID=44652020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014002693A MX2014002693A (es) | 2011-09-07 | 2011-09-07 | Uso de 1h-quinazolina-2,4-dionas para usarse en la prevencion o el tratamiento de epilepsia fotosensible. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2753331A1 (instruction) |
| JP (1) | JP2014525474A (instruction) |
| KR (1) | KR20140071405A (instruction) |
| CN (1) | CN103889427A (instruction) |
| AU (1) | AU2011376333A1 (instruction) |
| BR (1) | BR112014005210A2 (instruction) |
| CA (1) | CA2846503A1 (instruction) |
| IN (1) | IN2014DN01791A (instruction) |
| MX (1) | MX2014002693A (instruction) |
| WO (1) | WO2013036224A1 (instruction) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201609719A (zh) | 2014-05-28 | 2016-03-16 | 美國禮來大藥廠 | 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物 |
| CN109069480A (zh) | 2015-12-30 | 2018-12-21 | 阿达玛斯医药公司 | 用于治疗与癫痫相关的病症的方法和组合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0128996D0 (en) | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
| SE0201943D0 (sv) | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | New use |
| CN1871001A (zh) | 2003-10-31 | 2006-11-29 | 阿斯利康(瑞典)有限公司 | 炔烃ⅲ |
| CN1870999A (zh) | 2003-10-31 | 2006-11-29 | 阿斯利康(瑞典)有限公司 | 炔烃ⅰ |
| JP2007509935A (ja) | 2003-10-31 | 2007-04-19 | アストラゼネカ アクチボラグ | アルキンズｉｉ |
| AU2005215379A1 (en) | 2004-02-12 | 2005-09-01 | Merck & Co., Inc. | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 |
| GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
| GB0508319D0 (en) | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
| KR20080076962A (ko) | 2005-12-20 | 2008-08-20 | 노파르티스 아게 | 대사성 글루타메이트 수용체 조절제로서의 니코틴산 유도체 |
| BR112012010201A2 (pt) * | 2009-11-03 | 2017-08-08 | Lupin Ltd | formulação de libertação modificada da lacosamida |
-
2011
- 2011-09-07 IN IN1791DEN2014 patent/IN2014DN01791A/en unknown
- 2011-09-07 AU AU2011376333A patent/AU2011376333A1/en not_active Abandoned
- 2011-09-07 MX MX2014002693A patent/MX2014002693A/es not_active Application Discontinuation
- 2011-09-07 BR BR112014005210A patent/BR112014005210A2/pt not_active IP Right Cessation
- 2011-09-07 EP EP11757513.4A patent/EP2753331A1/en not_active Withdrawn
- 2011-09-07 WO PCT/US2011/050687 patent/WO2013036224A1/en active Application Filing
- 2011-09-07 JP JP2014529647A patent/JP2014525474A/ja not_active Withdrawn
- 2011-09-07 CN CN201180073318.7A patent/CN103889427A/zh active Pending
- 2011-09-07 KR KR1020147008752A patent/KR20140071405A/ko not_active Withdrawn
- 2011-09-07 CA CA2846503A patent/CA2846503A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN103889427A (zh) | 2014-06-25 |
| JP2014525474A (ja) | 2014-09-29 |
| BR112014005210A2 (pt) | 2017-03-21 |
| CA2846503A1 (en) | 2013-03-14 |
| IN2014DN01791A (instruction) | 2015-05-15 |
| KR20140071405A (ko) | 2014-06-11 |
| EP2753331A1 (en) | 2014-07-16 |
| WO2013036224A1 (en) | 2013-03-14 |
| AU2011376333A1 (en) | 2014-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201017345D0 (en) | Receptor antagonists | |
| PT2785706T (pt) | 4-fenil-piridinas substituídas para o tratamento de doenças relacionadas com o recetor de nk-1 | |
| UA116196C2 (uk) | Синтетичний міметик апеліну для лікування серцевої недостатності | |
| MX355543B (es) | Macrociclos peptidomiméticos. | |
| MX367341B (es) | Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades. | |
| EP2768305A4 (en) | 2,5-DISUBSTITUTED THIOMORPHOLIN OREXINE RECEPTOR ANTAGONISTS | |
| HK1209159A1 (en) | Methods of decellularizing bone | |
| JO3755B1 (ar) | تركيبات تستوستيرون | |
| MX370253B (es) | Composiciones de compuestos de jasmonato y métodos de uso de las mismas. | |
| IN2014CN04014A (instruction) | ||
| MX354820B (es) | Moduladores del receptor x del higado. | |
| CL2013002908A1 (es) | Uso de compuestos derivados de bencimidazol-4-carboxamida para el tratamiento profilactico de la neuropatia periferica inducida por quimioterapia . | |
| FR2979931B1 (fr) | Potelet de garde-corps ou d'echafaudage equipe d'un bloqueur perfectionne | |
| MX354818B (es) | Moduladores del receptor x del higado. | |
| PL2807170T3 (pl) | Limonoidy fragmaliny do leczenia dysfunkcji seksualnych | |
| PH12018500282A1 (en) | Cgrp receptor antagonists | |
| EP2771346A4 (en) | ISOXAZOLOPYRIDIN-orexin | |
| IN2014DN07984A (instruction) | ||
| HUE045270T2 (hu) | FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére | |
| IN2014DN00254A (instruction) | ||
| MY165088A (en) | Pharmaceutical compositions comprising alisporivir | |
| MX2014002693A (es) | Uso de 1h-quinazolina-2,4-dionas para usarse en la prevencion o el tratamiento de epilepsia fotosensible. | |
| GEP201706636B (en) | Galactagogue compositions based on phosphatidylserine | |
| SG11202111525XA (en) | Stable targeted integration | |
| WO2012106473A3 (en) | Dosing for treatment with anti-egfl7 antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |